NCT06170268 Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
| NCT ID | NCT06170268 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alzheimer's Disease and Related Disorders Association, Inc |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2022-10-20 |
| Primary Completion | 2032-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2022-10-20 with a primary completion date of 2032-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.
Eligibility Criteria
Inclusion Criteria: * Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations. * Patient is at least 18 years of age at the time of informed consent. * Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice. * If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies. * Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.
Contact & Investigator
Gil Rabinovici, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06170268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06170268 currently recruiting?
Yes, NCT06170268 is actively recruiting participants. Contact the research team at alz-net@acr.org for enrollment information.
Where is the NCT06170268 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06170268 clinical trial?
NCT06170268 is sponsored by Alzheimer's Disease and Related Disorders Association, Inc. The principal investigator is Gil Rabinovici, MD at University of California, San Francisco. The trial plans to enroll 20,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.